Song Xiaoxu, Qi Weiwei, Guo Jing, Sun Libin, Ding Aiping, Zhao Guanghui, Li Hui, Qiu Wensheng, Lv Jing
Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China.
Oncol Lett. 2020 Oct;20(4):46. doi: 10.3892/ol.2020.11905. Epub 2020 Jul 24.
Gastric cancer is one of the most common types of cancer; notably, gastric cancer is one of the top five malignancies with regards to incidence and mortality rates. The symptoms of early gastric cancer are not typical, exhibiting only slight upper abdominal discomfort. When the symptoms become more obvious, the lesion has usually progressed to an advanced stage. Notably, >90% of inpatients already have locally advanced or metastatic gastric cancer at the time of initial diagnosis, with limited treatment options for advanced gastric cancer. These options include chemotherapy, targeted therapy and immune checkpoint inhibitors (ICIs). With regards to ICIs, the clinical benefit of monotherapy for advanced gastric cancer is limited; however, combinations of ICIs and other therapies may have clinical benefit. Relevant clinical studies have demonstrated that combinations of ICIs with chemotherapy, anti-vascular targeted therapy or other molecular targeted therapies, and the use of two ICIs, improve outcomes for patients with advanced gastric cancer. This article is a review of progress in the use of ICIs in combination with other therapies for the treatment of gastric cancer. The purpose of this article was to advance gastric cancer immunotherapy and to improve the overall therapeutic benefit for patients with advanced gastric cancer.
胃癌是最常见的癌症类型之一；值得注意的是，就发病率和死亡率而言，胃癌是五大恶性肿瘤之一。早期胃癌的症状不典型，仅表现为轻微的上腹部不适。当症状变得更加明显时，病变通常已进展到晚期。值得注意的是，>90%的住院患者在初次诊断时已患有局部晚期或转移性胃癌，晚期胃癌的治疗选择有限。这些选择包括化疗、靶向治疗和免疫检查点抑制剂（ICI）。关于ICI，晚期胃癌单药治疗的临床获益有限；然而，ICI与其他疗法联合可能具有临床获益。相关临床研究表明，ICI与化疗、抗血管靶向治疗或其他分子靶向治疗联合，以及使用两种ICI，可改善晚期胃癌患者的预后。本文综述了ICI与其他疗法联合用于治疗胃癌的进展。本文的目的是推进胃癌免疫治疗并提高晚期胃癌患者的整体治疗获益。
